Positive results of clinical trial of an immune therapy in dogs with bone cancer are being used to accelerate the development of the drug to treat children with the same cancer.
A Comparative Oncology It is the study of cancers that occur naturally in animals of company, such as dogs and cats, as models for the treatment of human diseases.
Animal cancers share characteristics with human cancers, such as osteosarcoma (bone cancer), prostate and breast cancers, non -hodgkin’s lymphoma and melanoma.
Now, the Biopharmaceutical company, based in New York, is focused on the development of immunoterapies for osteosarcoma and other solid tumors, using comparative oncology.
Through your Cheese-here2 – Treatment for canine osteosarcoma – the company expects to reach a Treatment for children with the same type of cancer.
As explained by HER2 therapies target the cancers that express human epidermal growth factor 2 (HER2), which include breast, esophageal, lung, ovarian, pancreas and osteosarcoma cancers. These cancers produce abnormally high levels of HER2 protein, which speeds up the growth and spread of the tumor.
The recent clinical trial of Therapies with Ost-HE2 in dogs with osteosarcoma in April at Molecular Therapydemonstrated that the Treatment prevented or delayed amputation, delayed tumor growth and metastases and improved survival.
The results suggest that Ost-HE2 is a less invasive and more directed approach to the treatment of this aggressive cancer.
“Our approach to comparative oncology, as a result of 96% genetic homology between human and canine osteosarcoma, leads us to believe that there is a significant potential for These canine data translate into humans in the treatment of primary and first -line metastatic osteosarcoma“, These Paul RomnessCEO and president of OST, to New Atlas.
Promising results
In January 2025, OST reported the results of its 2B phase clinical trials in Ost-Her2 humans for osteosarcoma that had spread to the lungs and had been completely surgically removed. Participants in the rehearsal were between 12 and 39 years old.
Treatment produced a statistically significant result in 12 -month survival (EFS), where an “event” is defined as the recurrence of metastatic osteosarcoma. In addition, Ost-HE2 had a significant and positive effect on global survival.
“Patients treated with Ost-HE2 have achieved the primary goal of EFs at 12 months in a statistically significant proportion to comparable historical control, as well as increasing the likelihood of survival one year and two years compared to comparable historical controls,” he said Robert Petit, PhDthe founding scientist of Ost-HE2 and the medical and scientific director of Os Therapies.
Hope for children
As a treatment for osteosarcoma in children, the OST-HE2 received the designation of Rare Pediatric Disease (RPDD) Food and Drug Administration (FDA) of the US, as well as the designations Fast Track e Orphan Drug FDA and the European Medicines Agency (EMA).
This year, the OST intends to submit a Biological License (BLA) request to FDA, a formal authorization request for introduce or distribute Ost-HE2 as treatment for osteosarcoma.
As with dogs, osteosarcoma is the most common primary bone cancer in humans.
Romness states that now the company is focused on “obtaining accelerated approval for Ost-Her2 in human osteosarcoma by the end of 2025.
